Stefan Fraenkel - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 14.2  0.00  0.00%

Vice President Head of Corporate Development

Mr. Stefan Fraenkel serves as Senior Vice President, Head of Corporationrationrate Development at Swedish Orphan Biovitrum AB . He joined the Company in 2009. He is also Board member of Akinion Pharmaceuticals. He was Management Consultant and has held several international managerial positions within Wyeth Pharmaceuticals 20012009
Age: 43    MBA    
46 86 97 20 00  http://www.sobi.com
Fraenkel holds a Doctorate of Philosophy degree in International Accounting and Management. Apart from that, he has obtained a MBA degree from Copenhagen Business School and a BS degree in Engineering from Chalmers Tekniska Hogskola.

Management Efficiency

The company has return on total asset (ROA) of 8.0 % which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 5.6 % meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.

Similar Executives

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.

Did you try this?

Run Cryptocurrency Center Now
   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Hide  View All  Next  Launch Cryptocurrency Center
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Top Management

Swedish Orphan Biovi Leadership Team
Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance

Swedish Orphan Performance Indicators